Information Provided By:
Fly News Breaks for June 7, 2018
Jun 7, 2018 | 07:58 EDT
Following the read-through from Proteostasis' (PTI) data for PTI-801 in CF patients on background Orkambi therapy, RBC Capital analyst Brian Abrahams reaffirmed his view that weakness in Vertex (VRTX) into the readout of similar Phase II CF study data from Galapagos (GLPG) is "unfounded" and presents a buying opportunity for Vertex shares. Abrahams has an Outperform rating and $202 price target on Vertex shares.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.